Supernus Pharmaceuticals Inc

SUPN

Equity

ISIN null / Valor 18393960

NASDAQ (2026-05-04)

USD 48.63+1.63%

Supernus Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Supernus Pharmaceuticals is a U.S.-based specialty pharmaceutical company (NASDAQ: SUPN) that researches, develops, licenses and commercializes branded prescription therapies for central nervous system disorders, particularly in neurology and psychiatry. Its commercial portfolio has included extended‑release antiseizure medicines and, more recently, Qelbree (viloxazine), a non‑stimulant treatment for attention‑deficit/hyperactivity disorder; the company also pursues development-stage candidates, formulation technologies and in‑licensing or partnership arrangements to expand its pipeline and product reach. Supernus generates revenue primarily from sales of its marketed products in the U.S. and from collaboration agreements, while investing in clinical programs aimed at expanding indications and developing new CNS therapies.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

48.1%1Y

33.3%3Y

61.6%5Y

Performance

36.2%1Y

36.2%3Y

35.3%5Y

Volatility